-
Indonesia to capture last-known wild Bornean rhino for IVF
-
No vaccine, conflict, mistrust: Ebola's return to DR Congo
-
USA, Australia eye World Cup knockout rounds, Brazil in action
-
AI museum brings sights, sounds and smells of the rainforest
-
Iran to lodge complaint with FIFA over World Cup restrictions
-
'Old dog' Slipper out of retirement for Wallabies' Nations Championship campaign
-
New Zealand minister defends fishers after two orcas killed in net
-
Mexico into World Cup last 32, Canada celebrate historic win
-
Seoul record leads most Asian markets higher, crude extends losses
-
Co-hosts Mexico first team into World Cup knockout rounds
-
Burnham wins key UK poll, paving way for bid to challenge PM Starmer
-
Erasmus under 'no illusions' as tough Springboks season kicks off
-
'Pico' Lopes -- Cape Verde defender's journey from Ireland to World Cup
-
100 Colombian guerrillas disarm in deal with leftist government
-
'Pretty special': captains eye Super Rugby glory in clash of top seeds
-
Football 'ambassador' and fan favorite: a duck becomes a star in Mexico
-
Ivory Coast's Diomande living World Cup dream, dealing with tragedy
-
Slipper out of retirement for Wallabies' Nations Championship campaign
-
Australia seek 'respect' from US amid World Cup 'layup' row
-
New Zealand's Payne joins Paraguayan powerhouse after Instagram fame
-
Japan doctor-turned-author moots amputations to ease care crunch
-
Clark seizes four-stroke lead at darkness-halted US Open
-
Fossils challenge assumptions on how animals adapted to land
-
From private enterprise to property: Cuba's reforms unpacked
-
Canada romp to first World Cup win, Switzerland thump Bosnia
-
'Last ride': US says goodbye to Air Force One as Qatari jet awaits
-
Venezuela govt, opposition hold US-backed talks on democratic transition
-
Gabriel tells Brazil to turn the page against Haiti at World Cup
-
Horror injury overshadows Canada's first World Cup win
-
Cuba adopts historic package of free-market reforms
-
Swiss wunderkind Manzambi scores 'childhood dream' brace
-
US faces tough path to new Iran nuclear deal
-
Good US Open shots not good enough for 2-over Scheffler
-
Cuba unveils historic package of free-market reforms
-
Subs send Swiss to World Cup rout of Bosnia-Herzegovina
-
Stokes set for England return in New Zealand finale - reports
-
McIlroy pleased with reduced green speeds in US Open winds
-
Quarantine over for almost all hantavirus ship passengers, crew
-
US stocks resume upward climb as dollar advances again after Fed outlook
-
Ex-presidents and stars, but no Trump, turn out for Obama Library
-
Stevens seizes US Open lead with McIlroy, Aberg one back
-
Al-Qaeda-linked jihadists attack Niger airport, 11 soldiers killed
-
'Big-game' Bellingham shows his worth for England at World Cup
-
New Zealand's Henry rocks England in 2nd Test after Phillips century
-
Vance warns Israel against criticizing US-Iran deal
-
Iran's supreme leader says approved deal as US lifts ports blockade
-
Australian qualifier Hijikata shocks Lehecka at Queen's Club
-
AI-generated videos use Down syndrome to make sales
-
O'Brien's royal century reward for sacrificing all for racing
-
Spurs sign Dutch defender Van Hecke from Brighton
Biden proposes huge expansion of weight loss drug access
Outgoing US President Joe Biden proposed Tuesday to give millions more Americans access to weight loss drugs -- but Donald Trump's incoming health chief looked set to shoot down the idea.
Under the massive US public health insurance programs Medicare and Medicaid, drugs like Ozempic and Wegovy are, for the most part, only available for overweight people with diabetes or heart disease.
But the White House said Biden wanted to make the game-changing medications widely available as a treatment for obesity itself -- expanding coverage to nearly 7.5 million older and lower-income Americans.
"For too many Americans, these critical treatments are too expensive and therefore out of reach," a White House official said, noting that 42 percent of Americans are obese.
The Department of Health and Human Services said separately in a statement that the "transformative medications" would improve the "health and quality of life for millions of people who have obesity."
The move would benefit 3.4 million Americans with Medicare, which gives health insurance to people mainly aged over 65. It would also help four million people eligible for assistance with Medicaid, which targets lower income residents, officials said.
But the last-gasp plan appears unlikely to survive given that Trump's incoming health secretary, Robert F. Kennedy Jr., has previously spoken out against the use of anti-obesity drugs.
In October Kennedy opposed a separate bill in Congress that would have expanded access to the medications, saying the money needed to do that would be better spent on improving nutrition.
"If we spent about one fifth of that giving good food, three meals a day to every man, woman and child in our country, we could solve the obesity and diabetes epidemic overnight," Kennedy said on Fox News.
- 'So stupid' -
He also accused the Danish makers of Ozempic and Wegovy, Novo Nordisk, of "counting on selling it to Americans, because we're so stupid and addicted to drugs."
Kennedy has attracted major controversy for his anti-vaccine activism and embrace of conspiracy theories -- but some of his proposals for improving American's diets have won praise from health campaigners and lawmakers.
Any plan to increase US public health insurance spending would also likely run foul of Trump's bid to slash government budgets and waste.
Trump said last week as he appointed celebrity TV doctor Mehmet Oz to head Medicare and Medicaid that Oz would "cut waste and fraud" in what he called "our Country's most expensive Government Agency."
The Republican has also named tech tycoon Elon Musk and entrepreneur Vivek Ramaswamy to head a so called "government efficiency" commission to cut costs across government.
Biden has taken a different tack during his sole term in office.
The Democrat has led a major drive to lower the exorbitant cost of US prescription medicines, and his success in forcing pharmaceutical giants to reduce the prices of some became a key plank of his reelection campaign before he dropped out in July.
In July, Biden called on Novo Nordisk and Eli Lilly to lower prices for diabetes and weight loss drugs, saying firms must stop "ripping off the American people."
N.Schaad--VB